Skip to Main Content

Paper Details

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Clin Cancer Res
10
2023
ATM, BRCA, BRCA1, BRCA2, Circulating, Circulating Tumor DNA, HRR, HRR gene, HRR) gene, Metastatic Castration-resistant Prostate Cancer, Olaparib, Patients, ctDNA, enzalutamide, mCRPC, metastatic castration-resistant prostate cancer, olaparib, patients, plasma, recombination
Author NameAffiliation
Johann S de BonoThe Institute of Cancer Research and Royal Marsden
Michael A CarducciJohns Hopkins Kimmel Cancer Center
Neeraj AgarwalHuntsman Cancer Institute, University of Utah (NCI-CCC)
Kim N ChiUniversity of British Columbia
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
  • 1 - 5

Datasets

Release 1.2